Journal of Food Bioactives, ISSN 2637-8752 print, 2637-8779 online
Journal website www.isnff-jfb.com

Review

Volume 27, September 2024, pages 33-43

Recent advances in the anticancer molecular mechanisms of bioactive components from tea: A review

Figures

Figure 1.
Figure 1. The bioactive components and bioactivities of tea.
Figure 2.
Figure 2. The structure of the main components in tea. (a) Catechins. (b) Caffine. (c) Theanine. (d) Tea polysaccharides.

Tables

Table 1. Summary and comparison of recent epidemiological articles of tea and cancer
 
Cancer typeObjectType of teaComparisonMetricResultP Value
Note: aHRs (Multivariable-adjusted hazard ratios), RR (Relative Risk), HR (Hazard ratio), OR (Odds ratio), CI (Confidence interval).
Liver cancer (Li et al., 2023)Chinese femalesTeaCumulative consume over 30kg vs noneaHRs (95%CI)0.56 (95% CI: 0.32–0.97)0.038
Liver cancer (Li et al., 2023)Chinese femalesGreen teaCumulative consume over 30kg vs noneaHRs (95%CI)0.54 (95% CI: 0.30–0.98)0.051
Bladder cancer (Al-Zalabani et al., 2022)OverallTeaLow vs noneHR (95%CI)0.87 (95% CI:0.77–0.98)0.004
Bladder cancer (Al-Zalabani et al., 2022)OverallTeaMiddle vs noneHR (95%CI)0.86 (95% CI:0.77–0.96)0.004
Bladder cancer (Al-Zalabani et al., 2022)OverallTeaHigh vs noneHR (95%CI)0.84 (95% CI:0.75–0.95)0.004
Ovarian cancer (Zheng et al., 2023)femaleBlack teaAny vs noneRR (95%CI)0.64 (95% CI:0.51–0.80)<0.001
Brain cancer (Song et al., 2019)AsiansTeaHigh vs lowRR (95%CI)0.64 (95% CI:0.21–2.02)0.026
Brain cancer (Song et al., 2019)AmericansTeaHigh vs lowRR (95%CI)0.80 (95% CI:0.76–1.50)0.595
Stomach cancer (Martimianaki et al., 2022)EuropeansTeaRegular consumption vs non-regular consumptionOR (95%CI)1.00 (95% CI:0.90–1.11)<0.001
Stomach cancer (Martimianaki et al., 2022)AsiansTeaRegular consumption vs non-regular consumptionOR (95%CI)0.62 (95% CI:0.48–0.81)<0.001
Stomach cancer (Martimianaki et al., 2022)Chinese and JapaneseTeaRegular consumption vs non-regular consumptionOR (95%CI)0.67 (95% CI:0.49–0.91)<0.001
Stomach cancer (Martimianaki et al., 2022)IraniansTeaRegular consumption vs non-regular consumptionOR (95%CI)0.50 (95% CI:0.29–0.86)<0.001
Stomach cancer (Martimianaki et al., 2022)AmericansTeaRegular consumption vs non-regular consumptionOR (95%CI)0.95 (95% CI:0.87–1.05)<0.001
Kidney cancer (Chen et al., 2022)JapaneseTea5cups/days vs rarelyHR (95%CI)0.75 (95% CI:0.51–1.12)0.39
Kidney cancer (Chen et al., 2022)Japanese malesTea5cups/days vs rarelyHR (95%CI)0.96 (95% CI:0.59–1.56)0.74
Kidney cancer (Chen et al., 2022)Japanese femalesTea5cups/days vs rarelyHR (95%CI)0.75 (95% CI:0.51–1.12)0.05
Prostate cancer (Sen et al., 2019)EuropeansTeaHigh vs lowHR (95%CI)0.98 (95% CI:0.90–1.07)>0.1
Prostate cancer (Sen et al., 2019)EuropeansTeaModerate vs lowHR (95%CI)0.98 (95% CI:0.91–1.05)>0.1
Breast cancer (Zhang et al., 2019)Chinese femalesGreen teaRegular consumption vs none consumptionHR (95%CI)0.27 (95% CI:0.09–0.86)<0.05
Breast cancer (Zhang et al., 2019)Chinese femalesBlack teaRegular consumption vs none consumptionHR (95%CI)0.29 (95% CI:0.04–2.08)<0.05
Breast cancer (Zhang et al., 2019)Chinese femalesOolong teaRegular consumption vs none consumptionHR (95%CI)1.07 (95% CI:0.49–2.32)>0.05

 

Table 2. The bioactive components in tea and related anticancer molecular mechanisms
 
Tea typeCompositionMolecular mechanismCancerReferences
Green teaGTPscirc MITF/miR-30e-3p/HDAC2 axisMelanomaWu et al., 2022
Green teaL-TheanineBMAL1MelanomaZhang et al., 2022
Green teaTheaninePGE2/COX-2/MPO/MDA/SOD/GPx/CAT/GRColorectal cancerMa et al., 2022
Green teaL-theanineERK/NF-κB/P65Prostate cancerSaedmocheshi et al., 2019
Green teaTea PolysaccharideDAB2Prostate cancerYang et al., 2019
Green teaTea PolysaccharideEB/mTOR/LAMP1Colon cancerZhou et al., 2021
Black teaHomogeneous polysaccharideA549/SMMC7721Lung cancerLiu et al., 2022
Green teaEGCGSTAT1Lung cancerLi et al., 2023
Golden-flowered teaPI3K-Akt/MAPKLung cancerWang et al., 2022
Green teaOTP-3EGFRLung cancerHuang et al., 2022
TeaTBs-CPI3K/AKT/mTORLung cancerWang et al., 2022
Green teaTheabrowninMAPK/JNK/P53Lung cancerXiao et al., 2022
Green teaEGCGEGFRLung cancerMinnelli et al., 2021
Black teaNRF2Lung cancerDatta et al., 2023
Huang qin teaIL-1β/IL-6/IL-10/TNF-αColorectal cancerShen et al., 2020
Green teaPI3K/AKTColorectal cancerZhang et al., 2020
Green teaEGCGSTAT3/CXCL8Colorectal cancerZhang et al., 2023; Luo et al., 2020
Green teaEGCGGRP5/NF-κB/miR-78 155p/MDR5Colorectal cancerLa et al., 2019
Pu-erh teaTheabrowninPI3K/AkT/Mtor/cyclin D1Colorectal cancerLeung et al., 2022
Green teaTheanineAkt/mTOR/JAK2/STAT3/Smad2Colorectal cancerShojaei-Zarghani et al., 2021
Cocoa teaPI3K/AktColorectal cancerGao et al., 2020
Green teamiRNA-181aProstate cancerSafari et al., 2022
Black teaTheaflavin-3,3′-digallate67LR/PKCδ/aSMaseProstate cancerSun et al., 2022
Green teaECGacetyl-CoA carboxylase/ATP citrate lyase/fatty acid/PI3K/AKT/mTORProstate cancerChen et al., 2021
Green tea(-)-ECZIP9Prostate cancerThomas and , 2021
Green teaEGCGCa2+Prostate cancerMarchetti et al., 2020
Green teaEGCGp53/p21/Bax/Bcl2Prostate cancerChen et al., 2019
TeaTLNTsROSBreast cancerChen et al., 2023
Gypenia pentaphylua teaGyp IAKT/GSK3β/β-cateninBreast cancerTan et al., 2022
Green teap53/p21Breast cancerSantos et al., 2021
Green teaEC/EGC/ECG/EGCGPTP1BBreast cancerKuban-Jankowska et al., 2020
Green teaEGCGArg-1/iNOS/NOX2/NF-κB/STAT3/ECM-receptor interaction/focal adhesionBreast cancerXu et al., 2020